Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.14 -0.74 (-2.86%)
Official Closing Price Updated: 7:00 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'
The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic. 
Via Benzinga
Topics Government
When AI Execs Say the Market Looks Bubbly
Market chatter about the frothiness of the AI market seems to be picking up as OpenAI CEO Sam Altman claims that he too sees a bubble forming. 
Via The Motley Fool
Topics Artificial Intelligence
Top 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts
Powell’s dovish Jackson Hole remarks signal that the Fed could cut rates as early as September, with markets now pricing an 80% chance of a 25 bps cut. 
Via MarketBeat
Topics ETFs Economy
Price Over Earnings Overview: Pfizer
 
Via Benzinga
This Is What Whales Are Betting On Pfizer
 
Via Benzinga
3 Stocks Under $50 Walking a Fine Line
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
Topics Artificial Intelligence
2 Reasons to Watch ZTS and 1 to Stay Cautious
Over the past six months, Zoetis’s shares (currently trading at $156.80) have posted a disappointing 7% loss, well below the S&P 500’s 8.6% gain. This might have investors contemplating their next... 
Via StockStory
Topics Government Stocks World Trade
The "Ten Titans" Stocks Now Make Up 38% of the S&P 500. Here's What It Means for Your Investment Portfolio
Massive growth stocks are driving the performance of the S&P 500, for better or for worse. 
Via The Motley Fool
Topics Economy Stocks
3 Unstoppable Dividend Stocks to Buy Right Now
Investors will get great dividends and more with these stocks. 
Via The Motley Fool
Topics World Trade
My 5 Favorite Stocks to Buy Right Now
Not every ticker worth owning at this time has raced to an uncomfortably high price. 
Via The Motley Fool
Topics Artificial Intelligence
Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years
HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a large smoking cessation market. 
Via Benzinga
Looking for the most active stocks in the S&P500 index on Thursday?
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties. 
Via Benzinga
My Top Dividend-Paying, Deep-Value Stock to Buy in August
You won't find many stocks with a juicier dividend and more attractive valuation than this big pharma stock. 
Via The Motley Fool
Topics Earnings Intellectual Property
2 S&P 500 Stocks to Own for Decades and 1 We Ignore
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns
San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet... 
Via MarketMinute
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?
Pfizer's yield is high, and so too is its payout ratio. 
Via The Motley Fool
3 Hyped Up Stocks That Fall Short
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
Intel, Nvidia, Twilio, Palo Alto Networks, Pfizer: What Sparked Heavy After-Hours Trading In These 5 Stocks?
Intel continued its winning run amid news of new strategic investment, while Nvidia saw activity as traders geared up for its quarterly results due next week. 
Via Stocktwits
Predicting the Next Rule Breaker Buyout
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table? 
Via The Motley Fool
Topics Artificial Intelligence
These S&P500 stocks are the most active in today's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
These 3 Dividend Stocks Have Yields Above 5%, Plus They Raise Their Payouts Every Year
These three businesses have been raising their payouts for at least 16 consecutive years. 
Via The Motley Fool
Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
2 Top Dividend Stocks to Buy on the Dip
These blue chip healthcare stocks could still deliver strong long-term returns. 
Via The Motley Fool
Topics Earnings Intellectual Property
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath. 
Via The Motley Fool
Topics Economy
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned. 
Via Benzinga
3 Long-Term Dividend Buys You Can Get for Under $50
Discover three undervalued dividend stocks under $50 that offer income, growth potential, and strong total returns for value investors 
Via MarketBeat
After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?
Pfizer beat expectations last quarter and it raised its guidance. 
Via The Motley Fool
Topics World Trade
Celcuity Expenses Jump 81 Percent
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.